Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation

AAPS PharmSciTech

Volumn 18, Issue 8, 2017, Pages 2919-2926

  Huang, Jiayuan ^a   Peng, Tingting ^a   Li, Yanrong ^a   Zhan, Zhengwen ^a   Zeng, Youmei ^a   Huang, Ying ^a   Pan, Xin ^a   Wu, Chuan Yu ^b   Wu, Chuanbin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

cubosome; glaucoma; ocular drug delivery; timolol maleate

Indexed keywords

GLYCEROL OLEATE; PILOCARPINE; POLOXAMER; TIMOLOL MALEATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; TIMOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA PERMEABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; EX VIVO STUDY; FEMALE; GLAUCOMA; HALF LIFE TIME; HISTOPATHOLOGY; IN VIVO STUDY; INTRAOCULAR PRESSURE; LEPORIDAE; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MICROSCOPY; MTT ASSAY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETENTION TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY; ZETA POTENTIAL; ANIMAL; CORNEA; DRUG EFFECT; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SMALL ANGLE SCATTERING; SYNTHESIS; X RAY DIFFRACTION;

ADMINISTRATION, OPHTHALMIC; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CORNEA; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; RABBITS; SCATTERING, SMALL ANGLE; TIMOLOL; X-RAY DIFFRACTION;

EID: 85018465184     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-017-0763-8     Document Type: Article

References (41)

1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.
2. Fishman P, Cohen S, Bar-Yehuda S. Targeting the A3 adenosine receptor for glaucoma treatment (review). Mol Med Rep. 2013;7(6):1723–5.
3. Hommer A, Hubatsch DA, Cano-Parra J. Safety and efficacy of adding fixed-combination brinzolamide/timolol maleate to prostaglandin therapy for treatment of ocular hypertension or glaucoma. J Ophthalmol. 2015;2015:131970.
4. McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye. 2014;28(3):249–58.
5. Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release. 2013a;165(1):82–9.
6. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12(6):486–90.
7. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliver Rev. 2006;58(11):1136–63.
8. Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. Journal of controlled release: official journal of the Controlled Release Society. 2013b;165(1):82–9.
9. Volotinen M, Korjamo T, Tolonen A, Turpeinen M, Pelkonen O, Hakkola J, et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. Basic Clin Pharmacol Toxicol. 2010;106(4):302–9.
10. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor Ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133(7):755–61.
11. Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18(5–6):290–7.
12. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. Aaps Pharmscitech. 2007;8(1).
13. Shafaa MW, Sabra NM, Fouad RA. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits. Biopharm Drug Dispos. 2011;32(9):507–17.
14. Yu SH, Wang QM, Wang X, Liu DD, Zhang WJ, Ye TT, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm. 2015;480(1–2):128–36.
15. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8
16. Randles EG, Bergethon PR. A photodependent switch of liposome stability and permeability. Langmuir. 2013;29(5):1490–7.
17. Ruozi B, Tosi G, Forni F, Fresta M, Vandelli MA. Atomic force microscopy and photon correlation spectroscopy: two techniques for rapid characterization of liposomes. Eur J Pharm Sci. 2005;25(1):81–9.
18. Rizwan SB, McBurney WT, Young K, Hanley T, Boyd BJ, Rades T, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21.
19. Muller F, Salonen A, Glatter O. Phase behavior of phytantriol/water bicontinuous cubic Pn3m cubosomes stabilized by laponite disc-like particles. J Colloid Interface Sci. 2010;342(2):392–8.
20. Rarokar NR, Saoji SD, Raut NA, Taksande JB, Khedekar PB, Dave VS. Nanostructured cubosomes in a thermoresponsive depot system: an alternative approach for the controlled delivery of docetaxel. AAPS PharmSciTech. 2016;17(2):436–45.
21. Salonen A, Moitzi C, Salentinig S, Glatter O. Material transfer in cubosome-emulsion mixtures: effect of alkane chain length. Langmuir. 2010;26(13):10670–6.
22. Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. Journal of controlled release: official journal of the Controlled Release Society. 2011;153(2):180–6.
23. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, et al. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. J Liposome Res. 2012;22(3):193–204.
24. Zhang J, Wang SL. Topical use of coenzyme Q (10)-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. Int J Pharm. 2009;372(1–2):66–75.
25. Rattanapak T, Young K, Rades T, Hook S. Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration. J Pharm Pharmacol. 2012;64(11):1560–9.
26. Karami Z, Hamidi M. Cubosomes: remarkable drug delivery potential. Drug Discov Today. 2016;21(5):789–801.
27. Murgia S, Bonacchi S, Falch AM, Lampis S, Lippolis V, Meli V, et al. Drug-loaded fluorescent cubosomes: versatile nanoparticles for potential theranostic applications. Langmuir. 2013;29(22):6673–9.
28. Dong YX, Dong P, Huang D, Mei LL, Xia YW, Wang ZH, et al. Fabrication and characterization of silk fibroin-coated liposomes for ocular drug delivery. Eur J Pharm Biopharm. 2015;91:82–90.
29. Falchi AM, Rosa A, Atzeri A, Incani A, Lampis S, Meli V, et al. Effects of monoolein-based cubosome formulations on lipid droplets and mitochondria of HeLa cells. Toxicol Res-Uk. 2015;4(4):1025–36.
30. Huang D, Wang LL, Dong YX, Pan X, Li G, Wu CB. A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles. Eur J Pharm Biopharm. 2014;88(1):104–15.
31. Baba K, Tanaka Y, Kubota A, Kasai H, Yokokura S, Nakanishi H, et al. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye. J Control Release. 2011;153(3):278–87.
32. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems—a review (part 2). Trop J Pharm Res. 2013;12(2):265–73.
33. Pople PV, Singh KK. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. Aaps Pharmscitech. 2006;7(4).
34. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10(1):289–96.
35. Li J, Wu L, Wu W, Wang B, Wang Z, Xin H, et al. A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int J Pharm. 2013;455(1–2):75–84.
36. Yang ZW, Tan YH, Chen MW, Dian LH, Shan ZY, Peng XS, et al. Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability. AAPS PharmSciTech. 2012;13(4):1483–91.
37. Fong WK, Hanley T, Boyd BJ. Stimuli responsive liquid crystals provide “on-demand” drug delivery in vitro and in vivo. J Control Release. 2009;135(3):218–26.
38. Han S, Shen JQ, Gan Y, Geng HM, Zhang XX, Zhu CL, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31(8):990–8.
39. Siekmann B, Bunjes H, Koch MH, Westesen K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int J Pharm. 2002;244(1–2):33–43.
40. Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1–2):177–82.
41. Zhen GL, Hinton TM, Muir BW, Shi SN, Tizard M, McLean KM, et al. glycerol monooleate-based nanocarriers for siRNA delivery in vitro. Mol Pharm. 2012;9(9):2450–7.